Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 14/20 | 0.53 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | SUV39H1 | O43463 | 1/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044721 | 0.89 | HCAR3 (0.66) | HCAR3AKR1C3 | |
| SCHEMBL6456865 | 0.86 | HCAR3 (0.60) | HCAR3HPGDHCAR2EHMT2 | |
| SCHEMBL6044299 | 0.81 | HCAR3 (0.67) | HCAR3PLA2G4AMAPTHPGDHCAR2 | |
| SCHEMBL6044668 | 0.78 | HCAR3 (0.77) | HCAR3PLA2G4AMAPTHPGDHCAR2 | |
| SCHEMBL23675185 | 0.74 | HCAR3 (0.56) | HCAR3MAPTHPGDHCAR2 | |
| SCHEMBL6043802 | 0.70 | HCAR3 (0.80) | HCAR3PLA2G4AMAPT | |
| SCHEMBL12243323 | 0.69 | CA1 (0.77) | MAPT | |
| SCHEMBL6043919 | 0.69 | HCAR3 (1.00) | HCAR3GAA | |
| SCHEMBL11559612 | 0.69 | HDAC1 (0.65) | HCAR3HCAR2 | |
| SCHEMBL1247450 | 0.68 | HCAR3 (0.57) | HCAR3MAPTHPGDHCAR2MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2004041274-A1 | BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | GCGR, GPR119, HMGCR | HCAR3 85/4885PLA2G4A 1645/4885MAPT 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.